Maralixibat chloride (SHP625 chloride) is an orally active ileal bile acid transporter (IBAT) inhibitor, intended for research use only. It is utilized for researching rare cholestatic liver diseases, including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia. It has been shown to reduce elevated sBA levels, improve liver function, and decrease liver tissue damage in rat models.
- Orally active IBAT inhibitor
- Used in research for cholestatic liver diseases
- Reduces sBA levels and improves liver function in models
- Decreases liver tissue damage in models